OTC
ITCI

Opera Trading Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Opera Trading Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,954
Closed -$64K – 167
2018
Q3 		$64K Buy
+2,954
New +$61.8K 0.01% 138

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Opera Trading Capital's ITCI Position: Q4 2018 in Review

Opera Trading Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2018, closing a stake of 2,954 shares — an estimated $64K sold.

Opera Trading Capital first reported a position in ITCI in Q3 2018 and held it in 1 quarter. The position peaked at $64K in Q3 2018. 127 funds tracked by Wall St. Rank hold ITCI as of Q4 2018.

  • Opera Trading Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2018 after selling out during the quarter.
  • Opera Trading Capital sold 2,954 Intra-Cellular Therapies Inc. shares in Q4 2018, an estimated $64K.
  • Opera Trading Capital first reported a position in Intra-Cellular Therapies Inc. in Q3 2018 and held it in 1 quarter.
  • Opera Trading Capital's Intra-Cellular Therapies Inc. position peaked at $64K in Q3 2018.
  • 127 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2018.

Based on Opera Trading Capital's 13F filing for Q4 2018, filed 22 Jan 2019.